28 May Q&A: Valuation of innovative companies: value of science or value of cash?
Conitnuing our series of online Q&A conversations. Join us and hear from leading industry experts, as they cover a wide range of topics relevant for emerging life science companies.
Next in the series, BaseLaunch moderates a discussion on Valuation of innovative companies: value of science or value of cash?
Value of science and value of cash are two different languages. Mastering both is key to agility, velocity and sustainability of innovative ventures.
The risk adjusted, net present value (rNPV) method is commonly known as the standard valuation method used within the biopharma area when evaluating assets beyond discovery stage. Well-calibrated, the rNPV method is a powerful tool to assess and challenge the company’s strategy. It also shows how the value develops over time and along reaching milestones.
Is it however what investors look at when making decisions?
For investors, it is crucial to understand how long it takes until the exit and what the potential return on investment might be. What are the conditions to harvest their investment? How might the multiple rounds and incentive packages impact their stake and value sharing rules? All along, it is about cap table and market liquidity.
When: 18.06.2020, 14:00 – 15:15
Where: Zoom webinar, link upon registration
Leonildo Delgado, BaseLaunch
Marie Petit, Villiger Valuation
Participation to the event is free of charge; however, your registration by 17.06.2020 is kindly required.